Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase 0/microdosing approaches: time for mainstream application in drug development?
Tal Burt, Graeme Young, Wooin Lee, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 11, pp. 801-818
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies
Filipa Mota, Camilo A. Ruiz-Bedoya, Elizabeth W. Tucker, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach
Shawn M. Cohen, Melissa B. Weimer, Ximena A. Levander, et al.
Journal of Addiction Medicine (2021) Vol. 16, Iss. 4, pp. 399-406
Closed Access | Times Cited: 40
High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis
Camilo A. Ruiz-Bedoya, Filipa Mota, Elizabeth W. Tucker, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 6
Open Access | Times Cited: 28
Better by design: What to expect from novel CAR-engineered cell therapies?
Vera Luginbuehl, Eytan Abraham, Karin Kovar, et al.
Biotechnology Advances (2022) Vol. 58, pp. 107917-107917
Closed Access | Times Cited: 22
A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept
Yuichi Sugiyama, Yasunori Aoki
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 9, pp. 1067-1076
Open Access | Times Cited: 11
Challenges in Permeability Assessment for Oral Drug Product Development
Mirko Koziolek, Patrick Augustijns, Constantin Berger, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2397-2397
Open Access | Times Cited: 11
ChemMORT: an automatic ADMET optimization platform using deep learning and multi-objective particle swarm optimization
Jiacai Yi, Ziyi Yang, Wentao Zhao, et al.
Briefings in Bioinformatics (2024) Vol. 25, Iss. 2
Open Access | Times Cited: 4
Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials
Linde Hoosemans, Marc Vooijs, Ann Hoeben
Cancers (2024) Vol. 16, Iss. 17, pp. 3021-3021
Open Access | Times Cited: 4
Advances in PET Imaging of α7 Nicotinic Receptors: From Radioligand Development to CNS Applications
Janus H. Magnussen
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 4
Open Access
Similarities and important distinctions between drug and behavioral intervention development
Hannah M. Fisher, Joseph G. Winger, Gregory P. Samsa, et al.
Discover Psychology (2025) Vol. 5, Iss. 1
Open Access
Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist
Erik Rein‐Hedin, Folke Sjöberg, Cecilia Ganslandt, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 3
The development and evolution of biological AMS at Livermore: a perspective
Graham Bench
Bioanalysis (2025), pp. 1-10
Open Access
The 3C (Cell Culture, Computer Simulation, Clinical Trial) Solution for Optimizing the 3R (Replace, Reduction, Refine) Framework during Preclinical Research Involving Laboratory Animals
Sounak Roy, Mubeena Parveen, Asis Bala, et al.
ACS Pharmacology & Translational Science (2025)
Closed Access
Incorporating Targeted Therapy Into Neuro-Oncology Practice
Marjolein Geurts, Juan Bautista Blaquier, Maarten M.J. Wijnenga, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Evaluation of dose-linearity in the systemic availability and pharmacokinetics of topically administered diclofenac: a 14C-microdosing study in healthy volunteers
Severin Mairinger, Mihye Kwon, Martin Bauer, et al.
Drug Metabolism and Disposition (2025), pp. 100091-100091
Open Access
Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective
Clive Wilson, Leon Aarons, Patrick Augustijns, et al.
European Journal of Pharmaceutical Sciences (2021) Vol. 172, pp. 106100-106100
Open Access | Times Cited: 21
Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic–TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions
Wooin Lee, Min‐Soo Kim, Jiyoung Kim, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 9, pp. 1145-1156
Open Access | Times Cited: 9
Phase I Studies: Innovations and Issues
Paul Beninger
Clinical Therapeutics (2024) Vol. 46, Iss. 2, pp. 85-89
Closed Access | Times Cited: 3
Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs
Xueyi Chen, Bhavatharini Arun, Oscar J. Nino-Meza, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Can preclinical drug development help to predict adverse events in clinical trials?
Lap Hing, Allan D. Burrows, Robin L. Anderson
Drug Discovery Today (2021) Vol. 27, Iss. 1, pp. 257-268
Closed Access | Times Cited: 19
Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma
Ingo K. Mellinghoff, Timothy F. Cloughesy
Journal of Clinical Oncology (2022) Vol. 40, Iss. 30, pp. 3510-3519
Open Access | Times Cited: 14
Strategic, feasibility, economic, and cultural aspects of phase 0 approaches
Tal Burt, Ad F. Roffel, Oliver Langer, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 6, pp. 1355-1379
Open Access | Times Cited: 13
Post-Pandemic Drug Discovery and Development: Facing Present and Future Challenges
Bruno O. Villoutreix
Frontiers in Drug Discovery (2021) Vol. 1
Open Access | Times Cited: 16
Macrophage PET imaging in mouse models of cardiovascular disease and cancer with an apolipoprotein-inspired radiotracer
Yohana C. Toner, Geoffrey Prévot, Mandy M. T. van Leent, et al.
npj Imaging (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 2
Low‐ and very low‐dose buprenorphine induction: new(ish) uses for an old(ish) medication?
Melissa B. Weimer, David A. Fiellin
Addiction (2022) Vol. 117, Iss. 6, pp. 1507-1509
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top